ORIGINAL ARTICLE

Beta-interferon exposure and onset of secondary progressive multiple sclerosis

T. Zhang[a], A. Shirani[b], Y. Zhao[c], M. E. Karim[d], P. Gustafson[d], J. Petkau[d], C. Evans[e], E. Kingwell[a], M. van der Kop[f], F. Zhu[a], J. Oger[a], H. Tremlett[a] and BC MS Clinic Neurologists

[a]*Division of Neurology and Brain Research Centre, Department of Medicine, University of British Columbia, Vancouver, BC, Canada;* [b]*University of Texas Southwestern Medical Center, Dallas, TX, USA;* [c]*Division of Neurology, Department of Medicine, MS/MRI Research Group, University of British Columbia, Vancouver, BC;* [d]*Department of Statistics, University of British Columbia, Vancouver, BC;* [e]*College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; and* [f]*Division of Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden*

Background and purpose: Beta-interferons (IFNβ) are the most widely prescribed drugs for patients with multiple sclerosis (MS). However, whether or not treatment with IFNβ can delay secondary progressive MS (SPMS) onset remains unknown. Our aim was to examine the association between IFNβ exposure and SPMS onset in patients with relapsing−remitting MS (RRMS).

Methods: A retrospective cohort study using British Columbia (Canada) population-based clinical and health administrative data (1985–2008) was conducted. RRMS patients treated with IFNβ ($n = 794$) were compared with untreated contemporary ($n = 933$) and historical ($n = 837$) controls. Cohort entry was the first clinic visit during which patients became eligible for IFNβ treatment (baseline). The outcome was time from baseline to SPMS onset. Cox regression models with IFNβ as a time-dependent exposure were adjusted for sex, and baseline age, disease duration, disability, *socioeconomic status and *comorbidities (*available for the contemporary cohorts only). Additional analyses included propensity score adjustment.

Results: The median follow-up for the IFNβ-treated, untreated contemporary and historical controls were 5.7, 3.7 and 7.3 years, and the proportions of patients reaching SPMS were 9.2%, 11.8% and 32.9%, respectively. After adjustment for confounders, IFNβ exposure was not associated with the risk of reaching SPMS when either the contemporary or the historical untreated cohorts were considered (hazard ratio 1.07; 95% confidence interval 0.93–1.48, and hazard ratio 1.04; 95% confidence interval 0.74–1.46, respectively). Further adjustments and the propensity score yielded results consistent with the main analysis.

Conclusions: Amongst patients with RRMS, use of IFNβ was not associated with a delayed onset of SPMS.

Introduction

Multiple sclerosis (MS) is a chronic degenerative disease of the central nervous system and the most common cause of neurological disability in young adults in the western world [1]. Despite recent advances in the treatment for MS, the beta-interferons (IFNβ) remain the most widely prescribed immunomodulatory drugs (IMDs) for patients with relapsing−remitting MS (RRMS) [2], the most common form of MS [3]. However, over time, patients with RRMS may transition to secondary progressive MS (SPMS) [4,5], synonymous with poor health outcomes and a diminished response to the currently licensed IMDs [6].

Correspondence: H. Tremlett PhD, Division of Neurology, Department of Medicine, University of British Columbia, Room S178, UBC Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada (tel.: +1 604 8220759; fax: +1 604 8220758; e-mail: helen.tremlett@ubc.ca).

The IFNβs were licensed for RRMS based on short-term randomized clinical trials which typically showed a one-third reduction in relapse rates and benefits on magnetic resonance imaging associated with IFNβ treatment [7,8]. However, the longer-term impact of the IFNβs has not been well established, especially with respect to delaying or preventing the onset of SPMS [9]. To date, three longitudinal cohort studies have examined the role of IFNβ in relation to SPMS in the post-marketing setting [10–12]. These studies are challenging to conduct and, whilst important, they may have suffered from fundamental biases including immortal time bias (different start times for the treated and untreated groups) [13,14] and selection bias [14].

Whether current drug treatments for RRMS can delay SPMS onset remains unknown. Indeed, the lack of treatment options to prevent or modify SPMS has been highlighted as a major unmet need by a recent international collaborative group [15]. To fill this critical knowledge gap, the impact of IFNβ exposure on SPMS onset in an MS cohort in British Columbia (BC), Canada, was examined.

Methods

Data sources

Study patients were selected from the British Columbia Multiple Sclerosis (BCMS) clinic database (established 1980) which collates information on both incident and prevalent cases, comprising approximately 80% of MS patients [16] in BC (until the end of 2004, the last year all MS clinics in BC participated). This database contains clinical information, including disability [the Expanded Disability Status Scale (EDSS) score], date of symptom onset, disease course, relapses and use of IMDs, and has been extensively used [3,4,17,18].

Additional information was obtained through province-wide registry linkages: IFNβ use was captured in both the BCMS database and BC's PharmaNet database [19], which contains information on outpatient prescriptions dispensed in BC since 1 January 1996. Comorbidity information was obtained via the Medical Service Plan (MSP) [20] and Discharge Abstract Database (DAD) [21]. The MSP files contain fee-for-service physician billing records, whilst the DAD contains hospital admission and discharge records; both use the International Classification of Disease system. Socioeconomic status (SES) was obtained from Census Geodata which enables neighbourhood income to be converted to SES estimates using Statistics Canada's algorithm [22,23]. Data linkage was performed at the individual level using each patient's unique personal health number, facilitated by Population Data BC.

Design and setting

This was a retrospective cohort study, using a similar approach to that outlined previously [18]. Briefly, the study cohort included adults with RRMS (according to the Poser or McDonald criteria) [24,25], registered with a BCMS clinic and eligible for IFNβ treatment between April 1985 and December 2004. Eligibility was adapted from the BC government's reimbursement policy (≥18 years, with RRMS and an EDSS ≤6.5). The cohort entry (baseline) was the first clinic visit at which eligibility was reached. Follow-up was to the study outcome (SPMS, described below) or the last recorded MS clinic visit prior to study end (31 December 2008), whichever came first. Figure 1 outlines the selection of individuals from the BCMS database.

Defining treated and untreated comparison cohorts

The IFNβ-treated cohort included those first eligible between July 1995 and December 2004 (IFNβ received Canadian approval in 1995). To minimize potential period effects and indication bias, two separate comparator cohorts were used – one contemporary and one historical. The contemporary cohort included patients first eligible but who remained unexposed to IFNβ between July 1995 and December 2004, whilst the historical cohort comprised those first eligible prior to IFNβ approval (April 1985–June 1995) but who remained unexposed to IFNβ during the study period.

Measuring IFNβ exposure

All IFNβs were considered as one therapeutic group; switching was not considered as stopping as long as the prescription gap was ≤3 months (<5% of patients had a gap >3 months).

Measure of study outcome

The study outcome was time from baseline to the onset of SPMS, determined clinically by the treating MS neurologist using the internationally recognized definition of SPMS, i.e. presence of a progressive course with or without superimposed relapses in patients with an initial relapsing–remitting disease course [5], as used in previous studies [4,10,11,26–28].

Figure 1 Selection of IFNβ-treated and untreated cohorts from the BCMS database for the main analysis. BCMS, British Columbia Multiple Sclerosis; IMDs, immunomodulatory drugs; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; IFNβ, beta-interferons; SPMS, secondary progressive multiple sclerosis. [a]The sum of the individual reasons for exclusion exceeds the total number of patients because some patients met more than 1 condition.

Comorbidity

The presence of comorbidity might be associated with both exposure and outcome (e.g. alter the decision surrounding IFNβ utilization or impact MS progression), and so was included as a baseline covariate using the Deyo validated adaptation of the Charlson comorbidity index [29].

Statistical analyses

Basic demographic and clinical characteristics of the three groups were compared using appropriate tests.

Cox proportional hazards regression models, with IFNβ exposure as a time-dependent variable, were used to assess the hazard of disease progression (time to SPMS onset). This approach allowed the time from baseline to the first IFNβ prescription as well as the time from stopping IFNβ to the end of follow-up to contribute to the untreated follow-up time. The models were adjusted for potential confounding factors including age, sex, disease duration, comorbidity index, SES and disability (indicated by the EDSS) at baseline. SES and the comorbidity index were only used to adjust the comparison between the treated and contemporary untreated cohorts as they were not available for the historical cohort. The proportional hazards assumption for baseline covariates was examined using log−log plots; no violations were found.

To investigate whether MS patients with certain baseline characteristics might benefit differently from IFNβ treatment, the association between IFNβ exposure and SPMS onset according to baseline characteristics was further examined. For this analysis, patient subgroups were defined using four clinically relevant baseline characteristics: sex (male, female); age (≤30 years, >30–45 years, >45 years); disease duration (≤2 years, >2–5 years, >5–10 years, >10 years); EDSS (≤1.5, 2–2.5, ≥3). Because relapses may impact MS progression within specific subgroups [17,30], the association according to annualized relapse rate [ARR (≤1, >1)] in the 2 years pre-baseline (the onset attack was not counted as a relapse) was also explored. Cox proportional hazards model results were compared with and without the interaction term between IFNβ exposure and the baseline characteristic of interest (all adjusted for the remaining four baseline characteristics).

Supplementary analyses

In order to test key assumptions as well as to fully explore the association between IFNβ exposure and onset of SPMS, several supplementary analyses were conducted (Data S1). Briefly, the association between IFNβ exposure and SPMS onset was also examined: (i) with adjustment for comorbidities using an alternative measure – the Expanded Diagnosis Cluster codes [31]; (ii) in relation to relapse history, with the ARR [18] in the 2 years pre-baseline included as an additional covariate in the Cox proportional hazards models developed in the primary analysis; (iii) using propensity score adjustments. In a final supplementary analysis, (iv) whether there were any underlying temporal trends in the risk of reaching SPMS which might confound the association between IFNβ exposure and the onset of SPMS was explored.

Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) (IBM SPSS Statistics for Windows, Version 20.0. Released 2011, IBM Corp., Armonk, NY, USA) and R [32] (version 3.0.2).

The University of British Columbia's Clinical Research Ethics Board approved the study, which includes informed patient consent.

Results

From a cohort of 4957, a total of 2564 patients were eligible for IFNβ treatment between April 1985 and December 2004. In total, 794 formed the IFNβ-treated cohort, 933 the contemporary control cohort and 837 the historical untreated cohort (Fig. 1). Of those included as contemporary controls, 110 (4%) filled a prescription for glatiramer acetate between cohort entry and end. Demographics were comparable between the excluded and included patients: 73.1% of excluded patients were female with a mean age at MS onset of 31.8 (SD 10.1) years versus 76.0% of included patients whose mean age at MS onset was 32.0 (SD 9.3) years.

Baseline differences between the treated and control groups were largely not clinically significant (Table 1). However, final results produced by multivariable models were adjusted for these baseline characteristics. Compared to the treated cohort, the contemporary untreated group had similar sex and EDSS score distributions, comorbidity status and SES, but were older, had a lower relapse rate in the 2 years pre-baseline and longer disease duration. The historical untreated group were slightly older, with a lower EDSS score and longer disease duration at baseline (Table 1).

The treated cohort contributed 2774 patient-years of IFNβ exposed time and 1882 patient-years of unexposed time. The contemporary and historical untreated cohorts contributed 4017 and 7033 patient-years of unexposed time, respectively. The follow-up time (eligibility date to the end of follow-up) differed between groups; it was considerably longer for the historical untreated cohort [median 7.3 years, interquartile range (IQR) 2.8–13.2 years]. The median follow-up time was 5.7 years (IQR 3.8–8.0 years) for the IFNβ-treated cohort and 3.7 years (IQR 1.6–6.6 years) for the contemporary untreated cohort.

In total, 9.2% of treated patients reached SPMS, whilst 11.8% of contemporary and 32.9% of historical untreated patients reached SPMS during the follow-up period. The median time to SPMS onset was 3.7 years for the treated cohort, 2.0 years for the contemporary untreated cohort and 4.4 years for the historical untreated cohort.

Exposure to IFNβ was not associated with the hazard of reaching SPMS when the IFNβ-treated and contemporary control groups were compared [adjusted hazard ratio 1.07; 95% confidence interval (CI) 0.93–1.48) (Fig. 2]. Similar findings were observed when comparing the treated and the historical untreated group (adjusted hazard ratio 1.04; 95% CI 0.74–1.46) (Fig. 2). Findings remained virtually unchanged when SES and the comorbidity index were also included as covariates in the contemporary analysis (Fig. 3).

No statistically significant differences in the associations between IFNβ exposure and SPMS onset were found across subgroups based on likelihood ratio tests (Fig. 4). However, for patients with an ARR > 1, there was a trend towards a lower hazard of reaching SPMS for IFNβ exposed versus unexposed time (hazard ratio 0.62; 95% CI 0.24–1.55 for the contemporary approach; hazard ratio 0.60; 95% CI 0.26–1.36 for the historical approach). This reduction was not observed in those with an ARR ≤ 1.

Results of supplementary analyses are detailed online (Table S1; Figs S1–S3). Briefly, no statistically significant association between IFNβ exposure and SPMS onset was found when either individual comorbidities or the ARR were included as additional covariates, or in the propensity score adjusted model. Finally, time from MS onset to SPMS was not significantly different across the different time periods explored (Table S1; Figures S2, S3).

Discussion

It was found that exposure to IFNβ was not associated with the clinical onset of SPMS in the 5–6 years following treatment initiation in a cohort of patients with

Table 1 Baseline demographic and clinical characteristics of the study cohorts[a]

Characteristics	IFNβ-treated patients (n = 794)	Contemporary untreated patients (n = 933)[b]	P value	Historical untreated patients (n = 837)[c]	P value
Sex, n (%)					
Male	187 (23.6)	218 (23.4)	0.96[d]	211 (25.2)	0.45[d]
Female	607 (76.4)	715 (76.6)		626 (74.8)	
Age at MS onset, years, mean (SD)	31.8 (9.1)	33.1 (9.5)	0.004[e]	31.0 (9.2)	0.07[e]
n (%)					
<20	57 (7.2)	67 (7.2)		85 (10.2)	
20–<30	324 (40.8)	313 (33.5)		329 (39.3)	
30–<40	266 (33.5)	337 (36.1)	0.02[d]	287 (34.3)	0.22[d]
40–<50	121 (15.2)	169 (18.1)		110 (13.1)	
≥50	26 (3.3)	47 (5.0)		26 (3.1)	
Disease duration, years					
Mean (SD)	6.0 (6.9)	8.5 (8.6)	<0.001[e]	7.9 (8.2)	<0.001[e]
Median (IQR)	3.1 (1.1–8.7)	5.8 (1.9–12.5)		5.1 (1.5–12.1)	
Age at baseline, years, mean (SD)	37.3 (9.1)	41.1 (10.1)	<0.001[e]	38.3 (9.7)	0.03[e]
n (%)					
<30	169 (21.3)	120 (12.8)		151 (18.0)	
30–<40	301 (37.9)	308 (33.0)	<0.001[d]	324 (38.7)	0.39[d]
40–<50	243 (30.6)	310 (33.2)		259 (30.9)	
≥50	81 (10.2)	195 (20.9)		103 (12.3)	
EDSS score					
Mean (SD)	2.2 (1.3)	2.1 (1.4)	0.07[e]	2.0 (1.4)	0.03[e]
Median (range)	2.0 (0–6.5)	2.0 (0–6.5)	0.03[f]	1.5 (0–6.5)	0.001[f]
N (%)					
0	80 (10.1)	121 (13.0)		93 (11.1)	
1–1.5	227 (28.6)	274 (29.4)	0.29[d]	327 (39.1)	<0.001[d]
2–2.5	270 (34.0)	319 (34.2)		197 (23.5)	
3–3.5	140 (17.6)	136 (14.6)		139 (16.6)	
4–4.5	39 (4.9)	35 (3.8)		36 (4.3)	
5–5.5	13 (1.6)	14 (1.5)		18 (2.2)	
6–6.5	25 (3.1)	34 (3.6)		27 (3.2)	
Annualized relapse rate in the 2 years before baseline[g]					
Mean (SD)	0.6 (0.6)	0.4 (0.5)	<0.001[e]	0.6 (0.6)	0.24[e]
Median (IQR)	0.5 (0–1.0)	0.5 (0–0.5)		0.5 (0–1.0)	
Follow-up time (eligibility date to the end of follow-up)[j]					
Mean (SD)	5.9 (2.9)	4.3 (3.1)	<0.001[e]	8.4 (6.0)	<0.001[e]
Median (IQR)	5.7 (3.8–8.0)	3.7 (1.6–6.6)		7.3 (2.8–13.2)	
Charlson comorbidity index[h]					
Median (range)	0 (0–3)	0 (0–3)		NA	
Score, n (%)					
0 (no comorbidity)	783 (98.6)	909 (97.4)	0.09[d]	NA	
≥1 (at least one comorbid condition)	11 (1.4)	24 (2.6)			
Neighbourhood income quintile,[i] n (%)					
1 (lowest income)	144 (18.8)	166 (18.7)			
2	130 (17.0)	180 (20.3)			
3	168 (21.6)	178 (20.1)	0.49[f]	NA	
4	166 (21.7)	181 (20.4)			
5 (highest income)	157 (20.5)	182 (20.5)			

IFNβ, beta interferons; EDSS, Expanded Disability Status Scale; IQR, interquartile range; NA, data not available/incomplete. [a]Baseline was considered as the first date a patient became eligible for IFNβ treatment; [b]untreated patients who first became eligible for treatment in the 'IFNβ era' (between July 1995 and December 2004); [c]untreated patients who first became eligible for treatment in the 'pre-IFNβ era' (between April 1985 and June 1995); [d]Pearson's chi-squared test; [e]Student's t test; [f]Mann–Whitney–Wilcoxon test; [g]if this period included multiple sclerosis symptom onset, this first attack was not included as a relapse; [h]Deyo adaptation of the Charlson comorbidity index [24], based on hospital admissions or physician visits in the 2 years prior to baseline and derived from the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, excluding hemiplegia, paraplegia and dementia to avoid misclassifying complications of MS as comorbidity. All relevant comorbidities are aggregated into a single variable theoretically ranging from 0 to 33; higher scores indicate greater burden of comorbidity; [i]used as a proxy for socioeconomic status. Data were missing for 20 patients in the IFNβ-treated cohort and 30 patients in the contemporary control cohort; [j]patients were followed until they reached the outcome of secondary progressive multiple sclerosis, or until their last MS clinic visit or start of participation in an MS 'disease-modifying drug' related clinical trial.

(a)   Interferon Beta Treated (*n* = 794) vs the Contemporary Untreated (*n* = 933) groups

Factors	Adjusted Hazard Ratio (95% CI)
[b]Beta-interferon-exposed time (vs. unexposed time)	1.07 (0.93 – 1.48)
[c]Baseline EDSS scores (vs. ≤ 1.5)	
≥2 and <3	2.04 (1.32 – 3.15)
≥ 3	4.27 (2.82 – 6.48)
Disease duration at baseline (per 10 years)	1.08 (0.90 – 1.29)
Age at baseline (per 10 years)	1.42 (1.20 – 1.68)
Female (vs. male)	0.57 (0.42 – 0.78)

(b)   Interferon Beta Treated (*n* = 794) vs the Historical Untreated (*n* = 873) groups

Factors	Adjusted Hazard Ratio (95% CI)
[b]Beta-interferon-exposed time (vs. unexposed time)	1.04 (0.75 – 1.46)
[c]Baseline EDSS scores (vs. ≤ 1.5)	
≥2 and <3	1.96 (1.47 – 2.60)
≥ 3	3.25 (2.51 – 4.22)
Disease duration at baseline (per 10 years)	1.06 (0.88 – 1.28)
Age at baseline (per 10 years)	1.44 (1.21 – 1.73)
Female (vs. male)	0.62 (0.49 – 0.78)

Figure 2 Multivariable time-dependent Cox regression analysis of potential factors associated with time to SPMS[a] onset for IFNβ-treated versus untreated cohorts. (a) IFNβ-treated (*n* = 794) versus the contemporary untreated (*n* = 933) group. (b) IFNβ-treated (*n* = 794) versus the historical untreated (*n* = 873) group. [a]SPMS, secondary progressive multiple sclerosis. [b]IFNβ, beta-interferons; IFNβ exposure was modelled as a time-dependent variable. [c]EDSS, Expanded Disability Status Scale score which ranged from 0 to 6.5 at baseline.

Factors	Adjusted Hazard Ratio (95% CI)
[c]Beta-interferon-exposed time (vs. unexposed time)	1.04 (0.75 – 1.46)
Age at baseline (per 10 years)	1.44 (1.21 – 1.72)
Female (vs. male)	0.52 (0.38 – 0.71)
Disease duration at baseline (per 10 years)	1.06 (0.88 – 1.28)
[d]Baseline EDSS scores (vs. ≤ 1.5)	
≥2 and <3	2.06 (1.32 – 3.22)
≥ 3	4.50 (2.93 – 6.92)
[e]Charlson comorbidity index score ≥1 (vs. 0)	1.29 (0.52 – 3.17)
Neighborhood income level (vs. quintile 1 [lowest income])	
Quintile 2	0.90 (0.55 – 1.47)
Quintile 3	0.82 (0.50 – 1.33)
Quintile 4	0.96 (0.61 – 1.53)
Quintile 5	1.03 (0.65 – 1.64)

Figure 3 Time-dependent Cox regression analysis of potential factors associated with time to SPMS[a] onset for IFNβ-treated versus the contemporary untreated cohort[b] (with additional adjustments for socioeconomic status and the Charlson comorbidity index). [a]SPMS, secondary progressive multiple sclerosis. [b]IFNβ, beta-interferons; IFNβ-treated patients, n = 794; contemporary untreated patients, n = 933. [c]IFNβ exposure was modelled as a time-dependent variable. [d]EDSS, Expanded Disability Status Scale score which ranged from 0 to 6.5 at baseline. [e]Deyo adaptation of the Charlson comorbidity index [24], based on hospital admissions or physician visits in the 2 years prior to baseline and derived from the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, excluding hemiplegia, paraplegia and dementia to avoid misclassifying complications of MS as comorbidity. All relevant comorbidities are aggregated into a single variable theoretically ranging from 0 to 33; higher scores indicate greater burden of comorbidity.

RRMS from British Columbia, Canada. This finding was consistent regardless of whether a contemporary or a historical (pre- versus post-IFNβ era) untreated comparison cohort was considered or if propensity score adjustment was performed. Further, none of the baseline characteristics considered could be identified as indicating a response to drug treatment with respect to reaching SPMS, including sex, age, disease duration, disability (EDSS) or ARR. Findings could also be considered as reassuring given that concerns were raised after the pivotal clinical trials of IFNβ were published that they might hasten SPMS onset [33,34]. No evidence was found to support this concern.

A limited number of previous post-marketing, longitudinal observational studies have also investigated the relationship between IFNβ exposure and time to reach SPMS and have suggested a beneficial association [10–12]. However, given the challenges in conducting rigorous pharmaco-epidemiological studies, these studies could be prone to particular methodological shortcomings. One study [10] followed 1504 patients with RRMS for up to 7 years, but the design was susceptible to immortal time bias due to differing

start times for the treatment and control groups [13], which was not accounted for in the propensity score analysis. An independent re-analysis that corrected for this reported no significant impact of IFNβ exposure on SPMS onset [13], and others have shown that a propensity score alone cannot address this imbalance in immortal time [13,35]. A more recent study examined the risk of reaching SPMS in 730 contemporary patients treated with IFNβ or glatiramer acetate from the Swedish MS Registry (MS onset 1995–2004) and compared them to 186 historical untreated patients from the Gothenburg Incidence Cohort (MS onset between 1950 and 1964) [11]. They reported a lower risk of reaching SPMS in the contemporary treated cohort compared to the historical untreated cohort, although the authors reported that it was 'difficult to disentangle' period effects from possible drug effects [11]. The differences in time periods between the two groups was compounded further by their selection from disparate populations [11]; the earlier incidence cohort was population-based from one region in Sweden, whereas the later treated cohort represented patients from different regions within a registry which

(a) Interferon Beta Treated (*n* = 794) vs the Contemporary Untreated (*n* = 933) groups

[a]Baseline characteristics	Outcome rate (n/N, [%])	Hazard ratio (95% CI)[c]	P value[d]
Sex			
Male	61/405 (15.1)	1.19 (0.69 – 2.07)	0.87
Female	122/1322 (9.2)	1.00 (0.67 – 1.50)	
Age (years)			
≤30	16/346 (4.6)	1.81 (0.68 – 4.84)	
>30–45	91/922 (9.9)	1.24 (0.80 – 1.91)	0.28
≥45	76/459 (16.6)	0.69 (0.37 – 1.26)	
Disease duration (years)			
≤2	27/548 (4.9)	1.31 (0.60 – 2.84)	
>2–5	39/356 (11.0)	0.92 (0.46 – 1.82)	0.95
>5–10	47/353 (8.0)	0.93 (0.48 – 1.82)	
>10	70/470 (14.9)	1.15 (0.68 – 1.94)	
[b]EDSS			
≤1.5	32/702 (4.6)	1.34 (0.62 – 2.93)	
>2–<3	61/589 (10.4)	1.56 (0.91 – 2.66)	0.22
≥3	90/436 (20.6)	0.76 (0.47 – 1.22)	
[b]ARR			
≤	163/1549 (10.5)	1.15 (0.81 – 1.63)	0.21
>	20/178 (11.2)	0.62 (0.24 – 1.55)	

Scale: 0 1 2 3 4 5 6
← Favours interferon beta exposed time   Favours unexposed time →

(b) Interferon Beta Treated (*n* = 794) vs the Historical Untreated (*n* = 873) groups

[a]Baseline characteristics	Outcome rate (n/N, [%])	Hazard ratio (95% CI)[c]	P value[d]
Sex			
Male	109/398 (27.4)	1.20 (0.71 – 2.03)	0.38
Female	239/1233 (19.4)	0.95 (0.63 – 1.42)	
Age (years)			
≤30	49/387 (12.7)	1.18 (0.54 – 2.57)	
>30–45	205/933 (22.0)	1.09 (0.72 – 1.64)	0.54
≥45	94/311 (30.2)	0.82 (0.44 – 1.52)	
Disease duration (years)			
≤2	75/544 (13.8)	0.74 (0.38 – 1.43)	
>2–5	67/349 (19.2)	1.08 (0.56 – 2.09)	0.58
>5–10	77/351 (24.4)	1.10 (0.58 – 2.11)	
>10	129/423 (30.5)	1.17 (0.70 – 1.94)	
[b]EDSS			
≤1.5	96/727 (13.2)	1.02 (0.50 – 2.09)	
>2–<3	98/467 (21.0)	1.21 (0.73 – 2.03)	0.54
≥3	154/437 (35.2)	0.90 (0.57 – 1.44)	
[b]ARR			
≤	294/1406 (20.9)	1.13 (0.79 – 1.63)	0.12
>	54/225 (24.0)	0.60 (0.26 – 1.35)	

Scale: 0 1 2 3
← Favours interferon beta exposed time   Favours unexposed time →

Figure 4 Association between IFNβ exposure and onset of SPMS amongst IFNβ-treated patients and untreated patients according to each baseline characteristic. (a) IFNβ-treated (*n* = 794) versus the contemporary untreated (*n* = 933) group. (b) IFNβ-treated (*n* = 794) versus the historical untreated (*n* = 873) group. [a]Baseline was considered as the first clinic visit when a patient became eligible for beta interferon (IFNβ) treatment. [b]EDSS, Expanded Disability Status Scale; ARR, annualized relapse rate. [c]The hazard ratio of IFNβ exposure for the corresponding baseline characteristics level estimated using Cox regression models adjusting for the main effects of all the baseline characteristics, the IFNβ exposure as well as the interaction term between IFNβ exposure and the baseline characteristic of interest. [d]P values for testing the interaction between IFNβ exposure and the baseline characteristic of interest based on the likelihood ratio test which compares the models with and without the interaction term. [e]If this period included the onset attack, this was not counted as a relapse. [f]Outcome rates indicate how many patients were observed to reach the outcome (onset of SPMS) for each level of the baseline characteristic.

was not population-based, covering less than 60% of the Swedish MS population [11,36]. Finally, the IFNβ-treated and the historical untreated groups were imbalanced in terms of follow-up; the treated group was followed from the initiation of drug whereas the control group was followed from the onset of disease. This imbalance is a major problem in pharmaco-epidemiological studies and may bias the association between IFNβ exposure and SPMS [13].

Our study was designed to address these limitations. First, the cohort entry (start of follow-up) was comparable between groups and IFNβ exposure was treated as a time-dependent variable, taking into account the drug unexposed time period during follow-up and ensuring the same start times across groups [13]. Secondly, it was possible to select both the treated and untreated cohorts from the same population and explore whether a period effect could have influenced our findings. Thirdly, the inclusion of two separate untreated cohorts – a historical group and contemporary group (i.e. pre- and post-IFNβ era) – was another study strength; the historical cohort minimized the potential for indication bias, whilst the contemporary cohort provided another means of addressing potential period effects that can be difficult to measure. Fourthly, the longitudinal data with observations spanning up to 20 years and a population-based cohort of MS patients allowed sufficient follow-up [37]. Finally, it was possible to link our MS clinic cohort with provincial health administrative databases, providing a rich, reliable and objective data source that allowed for adjustment of important potential confounders such as comorbidity and SES.

The reasons why patients who were eligible for IFNβ but chose not to initiate therapy are probably complex and multifactorial, but may include perceived stable disease, unwillingness to receive a non-curative treatment, or needle phobia. Eligible patients who did not start IFNβ were found to be at a somewhat lower risk of reaching SPMS in both the main and supplementary analyses (findings did not reach significance), despite model adjustment for patients' characteristics, such as disease duration and disability (EDSS). This suggests residual confounding due to 'indication bias' [18], i.e., more rapidly progressing patients were more likely to be exposed to drug.

A trend towards a lower hazard of reaching SPMS for IFNβ exposed versus unexposed time was observed in patients with an ARR > 1, which suggests that IFNβ treatment may benefit patients whose disease is in an active inflammatory phase (i.e. a higher relapse rate). However, this finding did not reach statistical significance and further confirmatory studies are needed.

Our overall findings do concur with our previous study in which no association was observed between IFNβ exposure and disability progression indicated by time to confirmed and sustained EDSS scores of 6.0 and 4.0 [30]. In addition, findings are consistent with results from the 16-year follow-up of MS patients who were randomized to receive placebo or IFNβ treatment in a 2-year clinical trial which did not demonstrate a significant impact of IFNβ exposure on SPMS [26].

Our study has some limitations. Patients eligible for IFNβ treatment during the post- IFNβ era but who did not receive treatment may have a better clinical status compared to those who received treatment [18]. This confounding by indication was demonstrated in a re-analysis of the Italian study [10,13], which used a contemporary comparison cohort. However, by including a historical untreated group it was possible to minimize this potential issue. It was not possible to consider neutralizing antibodies, which when titres are high may be associated with reduced IFNβ effectiveness [38]. Although a variety of confounding factors were considered, the possibility cannot be ruled out that unmeasured confounders still existed. Only patients attending a BCMS clinic could be considered in our study population and it is possible that the presence of very mild or very severe disease would differentially prevent attendance at clinic for untreated patients. However, a systematic occurrence of one of these scenarios seems unlikely. Our findings were based on reaching SPMS. Although this is considered a relevant outcome and important landmark in the disease course of MS [26,27,39], it is primarily determined clinically and after a retrospective evaluation of disease activity. Although no formal validation of this outcome could be found, it is reassuring that the median time to SPMS from disease onset, as estimated by survival analyses, is comparable between studies from different regions and countries (averaging around 18–20 years across cohorts) [3,4]. Finally, the duration of follow-up was modest for the contemporary cohorts and the disease duration at entry was relatively short which may contribute to the relatively low occurrence of SPMS compared to that reported in previous population-based natural history studies (in which 40%–60% of patients developed SPMS over 10–20 years) [4].

In conclusion, no association was found between IFNβ exposure and SPMS onset in patients with RRMS in the 5–6 years following start of treatment. Our findings address concerns that were raised in the mid-1990s that these medications might hasten SPMS onset [33,34]. Further 'real-world' longitudinal studies are encouraged to confirm our findings, ideally with additional metadata such as genomic or biomarker information that might prove fruitful in identifying whether specific patient subgroups benefit from regular IFNβ use. Our findings also encourage the contin-

ued investigation of novel therapeutics to prevent or delay progressive MS.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Data S1. Supplementary analyses.
Figure S1. Time-dependent Cox regression analysis of potential factors associated with time to SPMS[a] onset for IFNβ-treated versus the contemporary untreated cohort[b] (with additional adjustment of SES and high impact/prevalence comorbidities).
Figure S2. Selection of the study population from the British Columbia Multiple Sclerosis clinic database: patients with relapsing-onset MS with symptom onset between 1975 and 1995.
Figure S3. Survival curves of time from MS symptom onset to SPMS occurrence within 10 years' disease duration, by 5-year onset intervals.
Table S1. Multivariable Cox regression analysis of potential factors affecting time to reach SPMS within 10 years from disease onset.

References

1. Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. *Postgrad Med J* 2005; **81:** 302–308.
2. The Multiple Sclerosis International Federation. An Atlas of MS. http://www.atlasofms.org/ (accessed 19/09/2013).
3. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. *Neurology* 2010; **74:** 2004–2015.

4. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. *Mult Scler* 2008; **14:** 314–324.

5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology* 1996; **46:** 907–911.

6. Ann Marrie R, Rudick RA. Drug insight: interferon treatment in multiple sclerosis. *Nat Clin Pract Neurol* 2006; **2:** 34–44.

7. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. *Mult Scler* 2002; **8:** 40–51.

8. Filippini G, Munari L, Incorvaia B, *et al*. Interferons in relapsing remitting multiple sclerosis: a systematic review. *Lancet* 2003; **361:** 545–552.

9. La Mantia L, Vacchi L, Di Pietrantonj C, *et al*. Interferon beta for secondary progressive multiple sclerosis. *Cochrane Database Syst Rev* 2012; **1:** CD005181.

10. Trojano M, Pellegrini F, Fuiani A, *et al*. New natural history of interferon-beta-treated relapsing multiple sclerosis. *Ann Neurol* 2007; **61:** 300–306.

11. Tedeholm H, Lycke J, Skoog B, *et al*. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. *Mult Scler* 2012; **19:** 765–774.

12. Bergamaschi R, Quaglini S, Tavazzi E, *et al*. Immunomodulatory therapies delay disease progression in multiple sclerosis. *Mult Scler* 2012; PMID: 22653657 [Epub ahead of print].

13. Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis . *Ann Neurol* 2008; **64:** 109–110.

14. Koch M, Mostert J, De Keyser J, Tremlett H, Filippini G. Interferon-beta treatment and the natural history of relapsing−remitting multiple sclerosis. *Ann Neurol* 2008; **63:** 125–126.

15. Fox RJ, Thompson A, Baker D, *et al*. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. *Mult Scler* 2012; **18:** 1534–1540.

16. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. *Neurology* 1992; **42:** 991–994.

17. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. *Neurology* 2009; **73:** 1616–1623.

18. Shirani A, Zhao Y, Karim ME, *et al*. Association between use of interferon beta and progression of disability in patients with relapsing−remitting multiple sclerosis. *JAMA* 2012; **308:** 247–256.

19. BC Ministry of Health [creator] (2010): PharmaNet. BC Ministry of Health [publisher]. Data Extract. Data Stewardship Committee (2010). http://www.popdata.bc.ca/data (accessed 19/03/2015).

20. British Columbia Ministry of Health [creator] (2010): Medical Services Plan (MSP) Payment Information File. Population Data BC [publisher]. Data Extract. MOH (2010). http://www.popdata.bc.ca/data (accessed 19/03/2015).

21. British Columbia Ministry of Health [creator] (2010): Discharge Abstract Database (Hospital Separations).

22. British Columbia Ministry of Health [creator] (2009): Consolidation File (MSP Registration and Premium Billing). Population Data BC [publisher]. Data Extract. MOH (2009). http://www.popdata.bc.ca/data (accessed 19/03/2015).

23. Wilkins R, Berthelot JM, Ng E. Trends in mortality by neighbourhood income in urban Canada from 1971 to 1996. *Health Rep* 2002; **13**(Suppl)**:** 1–27.

24. Poser CM, Paty DW, Scheinberg L, *et al*. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol* 1983; **13:** 227–231.

25. McDonald WI, Compston A, Edan G, *et al*. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. *Ann Neurol* 2001; **50:** 121–127.

26. Ebers GC, Traboulsee A, Li D, *et al*. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. *J Neurol Neurosurg Psychiatry* 2010; **81:** 907–912.

27. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. *Lancet* 1998; **352:** 1491–1497.

28. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. *Neurology* 2001; **56:** 1496–1504.

29. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992; **45:** 613–619.

30. Shirani A, Zhao Y, Karim ME, *et al*. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. *Eur J Neurol* 2013; **21:** 835–844.

31. British Columbia Ministry of Health [creator] (2009): Adjusted Clinical Groups. Population Data BC [publisher]. Data Extract. Version 5. MOH (2011). http://www.popdata.bc.ca/data (accessed 19/03/2015).

32. R Core Team. *R: A Language and Environment for Statistical Computing*, Version 3.0.2. Vienna, Austria: R Foundation for Statistical Computing, 2013. http://www.R-project.org/. [computer program].

33. Goodkin DE. Interferon beta treatment for multiple sclerosis: persisting questions. *Mult Scler* 1996; **1:** 321–324.

34. Rolak LA. IFNB in MS. *Neurology* 1996; **47:** 1110.

35. Dafni U. Landmark analysis at the 25-year landmark point. *Circ Cardiovasc Qual Outcomes* 2011; **4:** 363–371.

36. Marrie RA. Observational studies of treatment effectiveness: useful, useless or somewhere in between? *Mult Scler* 2013; **19:** 707–708.

37. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. *JAMA* 2011; **305:** 2462–2463.

38. Sorensen PS. Neutralizing antibodies against interferon-beta. *Ther Adv Neurol Disord* 2008; **1:** 125–141.

39. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. *Lancet Neurol* 2006; **5:** 343–354.